Plain-English translation of NCT07242664 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This trial is testing a new long-acting insulin called GZR33 to see how well it works in people with type 1 diabetes. Researchers want to compare how GZR33 performs compared to insulin degludec, an insulin that's already available. The study will measure how the body uses and responds to the medication over time.
People with type 1 diabetes need insulin to survive, but current options don't work perfectly for everyone. This trial aims to understand whether this new treatment could offer a better or different option for managing blood sugar.
You likely qualify if…
You likely don't qualify if…
You would take one insulin for 6 days, then stop and take a break (wash-out period), then take the other insulin for 6 days. Half the participants start with the new medication first, and the other half start with the existing one — this helps researchers compare them fairly. During the study, you'll have visits where researchers check your blood sugar levels, measure how your body responds to each medication, and watch for any side effects.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
Germany
Phase
Safety & dosing
Sponsor
Gan and Lee Pharmaceuticals, USA
Enrollment target
~12 participants
Started
October 2025
Primary completion
February 2026
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 64 Years
Last updated on clinicaltrials.gov in November 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Andre Feldmann
Gan and Lee Pharmaceuticals, USA
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.